18 results
424B5
IFRX
InflaRx N.V.
13 Apr 23
Prospectus supplement for primary offering
8:48am
and recruit immune cells to sites of infection. Activation of the complement system ultimately results in the cleavage of C5, which leads
424B5
IFRX
InflaRx N.V.
11 Apr 23
Prospectus supplement for primary offering
4:11pm
pathogens and recruit immune cells to sites of infection. Activation of the complement system ultimately results in the cleavage of C5, which leads
6-K
EX-99.1
IFRX
InflaRx N.V.
9 Nov 22
Current report (foreign)
7:52am
continued to recruit new patients and locate new clinical trial sites. Business travel, however, has been significantly reduced and widely replaced by other
424B5
tfj1sey7
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
qbdlza m2o9iqhdvb0
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
3edn1c5g1
24 Feb 21
Current report (foreign)
4:16pm
424B5
4redywuzb
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
mnwxst8v0 h4
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.3
7rmk0ia22oh
14 Aug 19
Current report (foreign)
4:16pm
20-F/A
bkq4vpz5mfpz4tq0cw4
29 Mar 19
Annual report (foreign) (amended)
4:23pm
424B4
iy4k 3on6
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
yrvlnw2g2wfn xep
2 May 18
Registration statement (foreign)
7:10am
20-F
vmc7ax
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next